Novartis' breast cancer treatment Kisqali has gained final EU approval today - and the company is confident it can follow this with a swift reimbursement recommendation from the UK's NICE.<
NICE has caused controversy by rejecting Pfizer’s Besponsa – a blood cancer drug that can give patients the chance to receive a potentially curative bone marrow transplant.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
